<DOC>
	<DOCNO>NCT00062946</DOCNO>
	<brief_summary>The purpose study measure molecules cell interact chemical nervous system , call dopamine . Investigators obtain two kind image brain-a position emission tomography ( PET ) scan magnetic resonance imaging ( MRI ) scan . Thirty-eight participant age 18 45 enrol study . They must history medical psychiatric illness , include substance abuse . Participants four appointment NIH . On first visit , undergo physical exam , medical history , lab test . The second third visit involve PET scan fourth visit involve MRI scan . Participants compensate $ 430 involvement study .</brief_summary>
	<brief_title>PET Imaging Dopamine Healthy Study Participants</brief_title>
	<detailed_description>Abnormalities dopaminergic function implicate number neurological psychiatric illness , include Parkinson 's disease , schizophrenia , psychostimulant dependence syndrome . Functional image positron emission tomography ( PET ) single photon emission compute tomography ( SPECT ) demonstrate feasibility vivo measurement distribution density dopamine ( DA ) D1 D2 receptor human . Besides simple measurement receptor density , show competition endogenous neurotransmitter radiolabeled tracer might provide tool estimate extracellular level neurotransmitter . However , study confine striatum . In protocol use PET tracer ( 18F ) fallypride , estimate stimulant-induced DA release baseline DA level striatum extrastriatal region compare baseline scan d-amphetamine alpha-methyl-para-tryosine ( AMPT ) adminstration . In addition , explore genetic factor determine synaptic DA level , allelic variation two gene regulate DA level , catechol-O-methyltransferase dopamine transporter , study . A recent study show oral administration d-amphetamine induced displacement ( 11C ) raclopride similar way commonly use method i.v . administration . The current protocol perform two step . First , method d-amphetamine administration determine study effect oral d-amphetamine binding ( 18F ) fallypride binding . If oral administration effectively displace radioligand binding , method apply subsequent study examine effect d-amphetamine AMPT individual subject . If study successfully detect influence DA level ( 18F ) fallypride binding , design applied study patient psychiatric neurological disorder .</detailed_description>
	<mesh_term>Amphetamine</mesh_term>
	<mesh_term>Dextroamphetamine</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Dopamine Agents</mesh_term>
	<mesh_term>alpha-Methyltyrosine</mesh_term>
	<criteria>INCLUSION CRITERIA : Age 1845 , inclusive In good general health basis history physical examination Normal screen laboratory study include thyroid function test , blood count , serum electrolyte , liver kidney function , urinalysis Normal ECG rest condition Normal blood pressure No illegal drug use base urine drug screen EXCLUSION CRITERIA : Pregnancy/Nursing Evidence active mental neurological illness Medically significant biochemical hematological abnormality screen laboratory study Abnormal ECG High Blood Pressure ( 140 systolic and/or 90 dystolic pressure ) History myocardial infarction angina pectoris Positive urine drug screen use alcohol within one week prior PET study History substance abuse dependence within 6 month Presence ferromagnetic metal body heart pacemaker Body weight 93 kg limit AMPT dose 4 g/ day ( subject four PET scan damphetamine AMPT administration ) Claustrophobia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 15, 2007</verification_date>
	<keyword>Thalamus</keyword>
	<keyword>Cerebral Cortices</keyword>
	<keyword>Quantification</keyword>
	<keyword>Reproducibility</keyword>
	<keyword>Dopamine Release</keyword>
	<keyword>( 18F ) Fallypride</keyword>
	<keyword>D-Amphetamine</keyword>
	<keyword>Alpha-Methyl-Para-Tyrosine ( AMPT )</keyword>
	<keyword>PET</keyword>
	<keyword>Dopamine D2 Receptor</keyword>
	<keyword>Healthy Volunteer</keyword>
	<keyword>HV</keyword>
</DOC>